Home/Filings/4/0002034679-25-000003
4//SEC Filing

Raben David 4

Accession 0002034679-25-000003

CIK 0002023658other

Filed

Oct 9, 8:00 PM ET

Accepted

Oct 10, 5:23 PM ET

Size

8.4 KB

Accession

0002034679-25-000003

Insider Transaction Report

Form 4
Period: 2025-10-09
Raben David
Chief Medical Officer
Transactions
  • Exercise/Conversion

    Common Stock

    2025-10-09$3.79/sh+22,000$83,37657,497 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2025-10-0922,000128,870 total
    Exercise: $3.79Exp: 2033-08-08Common Stock (22,000 underlying)
  • Sale

    Common Stock

    2025-10-09$18.45/sh22,000$405,90035,497 total
Footnotes (2)
  • [F1]This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025.
  • [F2]25% of the shares underlying this option vested on July 24, 2024, with the remainder vesting in twelve equal quarterly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

Issuer

Bicara Therapeutics Inc.

CIK 0002023658

Entity typeother

Related Parties

1
  • filerCIK 0002034679

Filing Metadata

Form type
4
Filed
Oct 9, 8:00 PM ET
Accepted
Oct 10, 5:23 PM ET
Size
8.4 KB